The Drug Discovery World Podcast DDW Highlights: 2 September 2024
Sep 2, 2024
Dive into groundbreaking advancements in drug discovery! Discover the international clinical trial exploring BioNTech’s mRNA lung cancer vaccine. Learn about innovative treatments making waves, including a monoclonal antibody and a new GLP-1 agonist for obesity. Plus, insights on a selective agonist for schizophrenia that could change lives. Join the buzz around these exciting clinical trials and the future of healthcare!
AI Snips
Chapters
Transcript
Episode notes
Nimasumab for Weight Loss
- Sky Bioscience is evaluating nimasumab, a peripheral CB1 inhibitor, for weight loss in a Phase 2 trial.
- The trial will assess its efficacy and safety, including GI tolerability and lean mass retention, differentiating it from GLP-1 and GIP drugs.
BioNTech's mRNA Cancer Vaccine Trial
- BioNTech's mRNA cancer vaccine, BNT116, is being investigated in a UK clinical trial for lung cancer.
- This immunotherapy trains the immune system to target cancer cells, minimizing harm to healthy cells unlike chemotherapy.
NBI-568 for Schizophrenia
- Neurocrine Biosciences' NBI-568, an oral muscarinic M4 selective agonist, showed positive Phase 2 results for schizophrenia.
- It significantly reduced PANSS scores with minimal GI side effects and no weight gain, offering a potential alternative to current treatments.